Pharmaceuticals, Biotechnology and Life Sciences
Achaogen’s multi-drug resistant (MDR) gram-negative product antibiotic candidate, plazomicin, met the objective for the U.S. Food and Drug Administration (FDA)…
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
Biocartis Group NV said on Monday, in accordance with the Belgian Transparency Act, that Sycomore Asset Management now holds 3.01% of the…
Mereo BioPharma Group, a clinical stage, UK-based biopharmaceutical company focused on rare diseases, is looking to strengthen its rare and specialty disease…
The research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for…
Novartis was denied bringing its eye drug combination of pegpleranib and Lucentis out of Phase III study for age-related vision…
Valneva said on Friday it will sent its Lyme disease vaccine candidate VLA15 to clinic. Phase I testing can begin…
Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that…
Horizon Pharma has announced that the Phase 3 trial, Steadfast (Safety, Tolerability and Efficacy of Actimmune Dose Escalation in Friedreich’s Ataxia study), evaluating Actimmune (interferon gamma-1b) for…
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application…